{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:01:17Z","timestamp":1780552877457,"version":"3.54.1"},"reference-count":24,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"Q1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>The PANORAMA survey aimed to assess current treatment practice for individuals with new diagnoses of relapsing-remitting multiple sclerosis (RRMS) in the United Kingdom and to explore variations in treatment approaches with an emphasis on escalation vs early high-efficacy treatment (HET) and treatment goals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>Health care professionals (HCPs) from the UK treating patients with RRMS took part in interviews facilitated by a structured questionnaire. Data were analyzed descriptively using quantitative or qualitative methods, as appropriate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Thirty-eight HCPs from 38 UK centers took part in the survey, including 20 MS consultants and 13 MS specialist nurses. Seventy-four percent (n = 28 of 38) of HCPs strongly agreed and 24% (9 of 38) agreed that early treatment is essential for better outcomes. HCPs reported that they currently treat a mean (SD) of 58.3% (20.8%) and 42.1% (21.8%) of patients with new diagnoses of RRMS with early HET or escalation approaches, respectively. Thirty-four percent (13 of 38) of HCPs reported a discrepancy between current treatment approach and the approach they would like to take, which would be 66.2% favoring early HET and 33.8% favoring escalation approaches. The factors influencing the choice of treatment approach were overall patient health profile (45%, 17 of 38) and patient choice (39%, 15 of 38). The most important treatment goals were to reduce relapses (63%, 24 of 38), delay disability progression (58%, 22 of 38), and maintain quality of life (50%, 19 of 38).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>The survey highlights variation among HCPs in the UK in current vs ideal use of escalation or early HET approaches and factors influencing choice of treatment approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.7224\/1537-2073.2023-079","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T23:55:52Z","timestamp":1736121352000},"page":"1-7","source":"Crossref","is-referenced-by-count":2,"title":["PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom"],"prefix":"10.7224","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-0672","authenticated-orcid":false,"given":"Nikos","family":"Evangelou","sequence":"first","affiliation":[{"name":"From the Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Mattoscio","sequence":"additional","affiliation":[{"name":"MS Service, Queen's Hospital, Barking Havering and Redbridge University Hospitals NHS Trust, Essex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Coutts","sequence":"additional","affiliation":[{"name":"Douglas Grant Rehabilitation Centre, Ayrshire Central Hospital, Ayrshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoharan","family":"Andiappan","sequence":"additional","affiliation":[{"name":"Real-World Evidence, OPEN Health, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Sawtell","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Ltd, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Rhys","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Ltd, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2025010707073270300_b1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.msard.2018.11.016","article-title":"Understanding treatment decisions from the perspective of people with relapsing remitting multiple sclerosis: a critical interpretive synthesis","volume":"27","author":"Eskyte","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"2025010707073270300_b2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler"},{"issue":"10","key":"2025010707073270300_b3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol"},{"key":"2025010707073270300_b4","unstructured":"National Institute for Health and Care Excellence\n          . Multiple sclerosis in adults: management. June22, 2022. Accessed November 21, 2024. https:\/\/www.nice.org.uk\/guidance\/ng220"},{"key":"2025010707073270300_b5","unstructured":"Scottish Medicines Consortium\n          . Multiple sclerosis. 2024. Accessed December 10, 2024. https:\/\/scottishmedicines.org.uk\/medicines-advice"},{"key":"2025010707073270300_b6","doi-asserted-by":"crossref","first-page":"102507","DOI":"10.1016\/j.msard.2020.102507","article-title":"Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis","volume":"46","author":"Manzano","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025010707073270300_b7","unstructured":"National Health Service Research Authority\n          . Governance arrangements for research ethics committees: 2020 edition. Updated December13, 2023. Accessed November 22, 2024. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/governance-arrangement-research-ethics-committees"},{"issue":"4","key":"2025010707073270300_b8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract Neurol"},{"issue":"9","key":"2025010707073270300_b9","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1111\/ene.15422","article-title":"Disability progression in multiple sclerosis patients using early first-line treatments","volume":"29","author":"Lefort","year":"2022","journal-title":"Eur J Neurol"},{"issue":"2","key":"2025010707073270300_b10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"2025010707073270300_b11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"1","key":"2025010707073270300_b12","doi-asserted-by":"crossref","first-page":"13333","DOI":"10.1038\/s41598-020-70255-z","article-title":"Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years","volume":"10","author":"Pulido-Valdeolivas","year":"2020","journal-title":"Sci Rep"},{"issue":"9","key":"2025010707073270300_b13","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability?","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"issue":"8","key":"2025010707073270300_b14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/jnnp-2022-329058","article-title":"Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis","volume":"93","author":"Wandall-Holm","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2025010707073270300_b15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"2025010707073270300_b16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"2025010707073270300_b17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/jpm12010119","article-title":"Escalation vs. early intense therapy in multiple sclerosis","volume":"12","author":"Casanova","year":"2022","journal-title":"J Pers Med"},{"issue":"9","key":"2025010707073270300_b18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/03007995.2021.1940911","article-title":"Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment","volume":"37","author":"Tencer","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2025010707073270300_b19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41687-022-00415-4","article-title":"Health-related quality of life in people with multiple sclerosis: how does this population compare to population-based norms in different health domains?","volume":"6","author":"Faraclas","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2025010707073270300_b20","doi-asserted-by":"crossref","first-page":"103137","DOI":"10.1016\/j.msard.2021.103137","article-title":"Fear of relapse in patients suffering from RRMS influence their quality of life","volume":"54","author":"Khatibi","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2025010707073270300_b21","doi-asserted-by":"crossref","first-page":"100484","DOI":"10.1016\/j.bbih.2022.100484","article-title":"Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: a systematic review and meta-analysis","volume":"24","author":"Peres","year":"2022","journal-title":"Brain Behav Immun Health"},{"key":"2025010707073270300_b22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12913-017-2341-x","article-title":"The hub-and-spoke organization design: an avenue for serving patients well","volume":"17","author":"Elrod","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"2025010707073270300_b23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013059","article-title":"Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? a systematic review","volume":"6","author":"Kelly","year":"2016","journal-title":"BMJ Open"},{"issue":"5","key":"2025010707073270300_b24","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1212\/WNL.0000000000200773","article-title":"Gender disparities in the career of neurology researchers","volume":"100","author":"Hall","year":"2023","journal-title":"Neurology"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/27\/Q1\/1\/3474552\/i1537-2073-27-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/27\/Q1\/1\/3474552\/i1537-2073-27-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:13:18Z","timestamp":1752786798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/panorama-a-2021-clinician-survey-of-treatment-approaches-for-people-with-new-diagnoses-of-relapsing-remitting-multiple-sclerosis-in-the-united-kingdom"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":24,"journal-issue":{"issue":"Q1","published-online":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2023-079","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}